FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson
Read more
Home »
Invega Sustenna
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. INVEGA SUSTENNA® Modified Release Aqueous Suspension for Intramuscular Injection Paliperidone palmitate Consumer
Read more